Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 3;26(5):977-979.
doi: 10.1093/neuonc/noae007.

Endoplasmic reticulum stress-related cancer-associated fibroblast confers adverse prognosis and therapeutic vulnerability in skull base chordoma

Mingxuan Li  1   2 , Yujia Xiong  1   3 , Jiwei Bai  1   2 , Yazhuo Zhang  1   2
Affiliations

Endoplasmic reticulum stress-related cancer-associated fibroblast confers adverse prognosis and therapeutic vulnerability in skull base chordoma

Mingxuan Li et al. Neuro Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1.
Figure 1.
ERS-CAF in skull base chordoma. (A) Kaplan–Meier survival curves of RFS and OS stratified by ERS-CAF score in RNA-Seq cohort. (B) The ESTIMATE score, immune score, and stromal score in high and low ERS-CAF groups. (C) Heatmap showing the proportions of immune and stromal cell in high and low ERS-CAF groups. (D) The expression of immune checkpoint in high and low ERS-CAF groups. (E) Comparisons of IC50 of potential therapeutic drugs between high and low ERS-CAF groups. nsP > .05; *P < .05; **P < .01. ERS-CAF, endoplasmic reticulum stress-related cancer-associated fibroblast; IC50, half maximal inhibitory concentration; OS, overall survival; RFS, recurrence-free survival.
See this image and copyright information in PMC

Comment in

References

    1. Zhang TL, Xia C, Zheng BW, et al.. Integrating single-cell and spatial transcriptomics reveals endoplasmic reticulum stress-related CAF subpopulations associated with chordoma progression. Neuro Oncol. 2023. - PMC - PubMed
    1. Bai J, Shi J, Zhang Y, et al.. Gene expression profiling identifies two chordoma subtypes associated with distinct molecular mechanisms and clinical outcomes. Clin Cancer Res. 2023;29(1):261–270. - PMC - PubMed
    1. Yoshihara K, Shahmoradgoli M, Martínez E, et al.. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. - PMC - PubMed
    1. Aran D, Hu Z, Butte AJ.. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. - PMC - PubMed
    1. Akinduro OO, Suarez-Meade P, Garcia D, et al.. Targeted therapy for chordoma: key molecular signaling pathways and the role of multimodal therapy. Target Oncol. 2021;16(3):325–337. - PMC - PubMed

Publication types